Related content

Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model

By Engin-Ustun Yaprak   Yılmaz Saynur   Timur Hakan   Ustun Yusuf   Moraloglu Ozlem   Deveer Ruya   Yılmaz Nafiye  

Gynecological Endocrinology, Vol. 29, Iss. 9, 2013-09 ,pp. : 851-854

Informa Healthcare

Access to resources Recommend Favorite

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

By lvarez Claudio   Alonso-Muriel Isabel   Garca Gabriela   Crespo Juana   Bellver Jos   Simn Carlos   Pellicer Antonio  

Human Reproduction, Vol. 22, Iss. 12, 2007-12 ,pp. : 3210-3214

Oxford University Press

Access to resources Recommend Favorite

Ovarian hyperstimulation syndrome

By Balen Adam  

Human Fertility, Vol. 10, Iss. 3, 2007-09 ,pp. : 189-189

Informa Healthcare

Access to resources Recommend Favorite

Understanding ovarian hyperstimulation syndrome

By Delbaere Anne   Smits Guillaume   Leener Anne   Costagliola Sabine   Vassart Gilbert  

Endocrine Journal, Vol. 26, Iss. 3, 2005-04 ,pp. : 285-289

Humana Press, Inc

Access to resources Recommend Favorite

Ovarian Hyperstimulation Syndrome

By Balen Adam  

Human Fertility, Vol. 16, Iss. 3, 2013-09 ,pp. : 143-143

Informa Healthcare

Access to resources Recommend Favorite